Matinas BioPharma(DE:6LJ)
€0.050.00 (-14.52%)
DE:6LJ
Matinas BioPharma financials statements
€0.05
At close:0.00 (-14.52%)
Matinas BioPharma (6LJ) Ratios
0 Followers
Matinas BioPharma Ratios
DE:6LJ's free cash flow for Q2 2026 was $-1.84M. For the 2026 fiscal year, DE:6LJ's free cash flow was increased by $0.00 and operating cash flow was $-1.84M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 |
| Quick Ratio | 2.79 | 3.01 | 5.93 | 8.06 | 11.73 |
| Cash Ratio | 2.73 | 2.73 | 1.83 | 1.61 | 4.84 |
| Solvency Ratio | -4.16 | -4.61 | -3.76 | -0.49 | -2.60 |
| Operating Cash Flow Ratio | -4.79 | -5.96 | -5.83 | -4.47 | -3.50 |
| Short-Term Operating Cash Flow Coverage | -10.07 | 0.00 | 0.00 | -33.67 | 0.00 |
| Net Current Asset Value | $ 1.70M | $ 2.97M | $ 9.69M | $ -7.70M | $ 42.16M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.19 | 0.23 | 0.14 | 0.05 | 0.08 |
| Debt-to-Equity Ratio | 0.28 | 0.38 | 0.18 | 0.11 | 0.09 |
| Debt-to-Capital Ratio | 0.22 | 0.28 | 0.16 | 0.10 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.49 | 1.67 | 1.30 | 2.15 | 1.17 |
| Debt Service Coverage Ratio | -14.21 | 0.00 | 0.00 | -42.59 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.22 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Debt Per Share | 3.71 | 0.59 | 0.82 | 0.95 | 1.12 |
| Net Debt to EBITDA | 0.27 | 0.23 | 0.05 | 0.11 | 0.67 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | -423.15% | -44090.91% |
| EBIT Margin | 0.00% | 0.00% | -2168.43% | -771.33% | -74954.55% |
| EBITDA Margin | 0.00% | 0.00% | -2082.57% | -760.16% | -74106.06% |
| Operating Profit Margin | 0.00% | 0.00% | -2168.43% | -771.33% | -74954.55% |
| Pretax Profit Margin | 0.00% | 0.00% | -2093.25% | -658.63% | -70554.55% |
| Net Profit Margin | 0.00% | 0.00% | -2093.25% | -658.63% | -70554.55% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -2093.25% | -658.63% | -70554.55% |
| Net Income Per EBT | 100.00% | 99.67% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 148.64% | 120.68% | 96.53% | 85.39% | 94.13% |
| Return on Assets (ROA) | -143.52% | -191.84% | -91.39% | -26.62% | -37.97% |
| Return on Equity (ROE) | -214.18% | -319.51% | -119.20% | -57.31% | -44.35% |
| Return on Capital Employed (ROCE) | -121.15% | -202.13% | -105.71% | -32.97% | -43.41% |
| Return on Invested Capital (ROIC) | -108.06% | -187.09% | -102.69% | -32.72% | -42.99% |
| Return on Tangible Assets | -209.07% | -233.61% | -110.56% | -28.18% | -40.87% |
| Earnings Yield | -322.49% | -977.24% | -48.84% | -19.37% | -10.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.45 | 10.23 | 0.00 | 26.99 | 15.56 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.22 | 0.56 | 0.01 |
| Asset Turnover | 0.00 | 0.00 | 0.04 | 0.04 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.05 | 0.08 | 0.00 |
| Cash Conversion Cycle | -252.14 | -35.67 | 0.00 | -13.53 | -23.45 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 252.14 | 35.67 | 0.00 | 13.53 | 23.45 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -19.21 | -3.26 | -3.52 | -4.42 | -3.62 |
| Free Cash Flow Per Share | -19.21 | -3.26 | -3.57 | -4.62 | -3.68 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -70.08 | -21.48 | -58.55 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -70.08 | -21.48 | -58.55 |
| Operating Cash Flow Coverage Ratio | -5.18 | -5.49 | -4.30 | -4.65 | -3.24 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -13.94 | -6.01 | -461.30 |
| Free Cash Flow Yield | -218.56% | -640.12% | -32.99% | -18.49% | -7.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.29 | -0.10 | -2.05 | -5.16 | -9.12 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 42.86 | 34.00 | 6432.73 |
| Price-to-Book (P/B) Ratio | 0.66 | 0.33 | 2.44 | 2.96 | 4.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.46 | -0.16 | -3.03 | -5.41 | -13.71 |
| Price-to-Operating Cash Flow Ratio | -0.46 | -0.16 | -3.07 | -5.66 | -13.94 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.02 | -0.03 | 0.13 | 2.51 |
| Enterprise Value Multiple | -0.06 | 0.10 | -2.00 | -4.36 | -8.01 |
| Enterprise Value | 562.84K | -1.91M | 45.74M | 105.65M | 195.95M |
| EV to EBITDA | -0.06 | 0.10 | -2.00 | -4.36 | -8.01 |
| EV to Sales | 0.00 | 0.00 | 41.74 | 33.14 | 5937.97 |
| EV to Free Cash Flow | -0.08 | 0.12 | -2.95 | -5.27 | -12.66 |
| EV to Operating Cash Flow | -0.08 | 0.12 | -2.99 | -5.52 | -12.87 |
| Tangible Book Value Per Share | 7.04 | 1.10 | 3.43 | 7.45 | 11.45 |
| Shareholders’ Equity Per Share | 13.23 | 1.56 | 4.43 | 8.45 | 12.49 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.25 | 0.74 | 0.01 |
| Net Income Per Share | -28.35 | -4.98 | -5.28 | -4.84 | -5.54 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.21 | 0.97 | 0.85 | 0.94 |
| Research & Development to Revenue | 0.00 | 0.00 | 13.22 | 5.23 | 441.91 |
| SG&A to Revenue | 0.00 | 0.00 | 9.46 | 3.48 | 308.64 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 4.51 | 1.64 | 130.06 |
| Income Quality | 0.68 | 0.66 | 0.67 | 0.91 | 0.65 |
Currency in USD

